Veloxis Pharmaceuticals A/S Announces Financial Results for the First Half 2013

Published: Aug 22, 2013

Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

Hørsholm, Denmark, 21 August, 2013

Veloxis Pharmaceuticals announces financial results for the first half 2013


-- LCP-Tacro(TM) has successfully demonstrated non-inferiority compared to tacrolimus (Prograf(R); Astellas Pharma) in its Phase III clinical trial, Study 3002. The Phase III randomized, double-blind and double-dummy study in 543 de novo kidney transplant recipients, with Prograf(R) as the comparator, met its primary efficacy and primary safety endpoints.

Help employers find you! Check out all the jobs and post your resume.

Back to news